Skip to main content
. 2015 Sep 17;126(20):2284–2290. doi: 10.1182/blood-2015-05-643320

Table 5.

Response rate in all intent-to-treat patients and by cytogenetic abnormalities

Response category, n (%) All evaluable patients, N = 32 Hyperdiploid, n = 10 Del(13), n = 9 Del(17p), n = 5
ORR 16 (50) 5 (50) 1(11) 4 (80)
VGPR 5 (16) 1 (10) 1(11) 1 (20)
PR 11 (34) 4 (40) 0 3 (60)
MR 5 (16) 3 (30) 3 (33) 0
SD 8 (25) 2 (20) 5 (56) 1 (20)
PD 3 (9) 0 0 0

PD, progressive disease; SD, stable disease.